1887
Volume 2007, Issue 1
  • ISSN: 0253-8253
  • E-ISSN: 2227-0426

Abstract

Background: this work aims at determining the efficacy of modified CHOP combination in which Vinorelbine (Navelbine) replaces Vincristine for the treatment of aggressive Non-Hodgkin's Lymphomas (NHL).

Patients and methods: This open label pilot study included 19 patients with aggressive NHL and one patient with low grade NHL who were treated with the new combination which we abbreviated as P-CAN (Prednisolone 100 mg/day PO day 1-5, Cyclophosphamide 750 mg/m2 i.v day 1, Adriamycin (Doxorubicin) 60 mg/m2 i.v day 1, Navelbine (Vinorelbine) 30 mg/m2 i.v day). The patients1 were 13 males and 6 females, mean age 50 years (34-65), performance state 0-2, International Prognostic Index (IPI) 0-3. Seven patients Stage I, one patient Stage II, eight patients Stage III and 3 patients in Stage IV. 14 patients with nodal disease and five patients with extra-nodal disease. They received total of 97 cycles of the chemotherapy (3-7 cycles).

Results: 18 out of 19 patients achieved complete response (CR). In one patient the response could not be assessed, one patient progressed while on treatment. Toxicity was mainly hematological. The 3 years overall survival (OS) and disease free survival (DFS) was 83%.

Conclusion: P-CAN is an effective, well tolerated combination in chemo-naive aggressive NHL. The addition of Vinorelbine to steroid, Adriamycin, and Cyclophosphamide seems improve the response. Further larger trials are needed to study this combination and its impact on longer overall survival.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2007.1.14
2007-06-01
2019-10-17
Loading full text...

Full text loading...

References

  1. 1. Harris   NL., , Jajfe   ES., , Diebold   J. , et al. , The WHO classification of neoplastic disease of the haemopoetic and lymphoid tissues: report of the clinical advisory committee meeting Airlie House, Virginia, Nov. 1997. . Histopathology . 2000; ;36: : 69– 87 .
    [Google Scholar]
  2. 2. Harris   NL., , Jajfe   ES., , Stein   H. , et al. , A revised European-American Classification oflyhphoid neoplasm a proposal from the international Lymphoma study group. . Blood . 1994; ;84: : 1361– 1392 .
    [Google Scholar]
  3. 3. Laurence   E., , Carol   S., , Rosenberg   SA. . Combination chemotherapy of diffuse histiocytic Lymphoma with cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP). . Cancer . 1978; ;42: : 1705– 1710 .
    [Google Scholar]
  4. 4. Armitage   JO. . Treatment of Non-Hodgkins lymphoma. . N Eng J Med . 1993; ;328: : 1023– 1030 .
    [Google Scholar]
  5. 5. Richard   I., , Ellen   R., , Steve   D. , et al. , Comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate or high grade NHL. . N Eng J Med.   1993; ;328: : 1002– 1006 .
    [Google Scholar]
  6. 6. Leveque   D., , Tehl   F. , Clinical pharmacokinetics . 1996; ;31: 3 : 184– 197 .
    [Google Scholar]
  7. 7. Budman   DR. . Vinorelbine: Athird generation vinca alkaloid. . Cancer Investigation.   1997; ;15: : 475– 490 .
    [Google Scholar]
  8. 8. Binet   S., , Chaineau   E., , Fellous   A. , et al. , Immunofluorecence study of the action of Vinorelbine Vincristine, and Vinblastine on mitotic axonal microtubules. . Int. J Cancer.   1990; ;46: : 262– 266 .
    [Google Scholar]
  9. 9. Toso   C., , Lindley   C. . Vinorelbine: Anovel vinca alkaloid. . Am J Health Syst Pharm.   1995; ;52: 12 : 1287– 1304 .
    [Google Scholar]
  10. 10. Jones   SF., , Burris   HA 3d. . Vinorelbine a new antineoplastic drug for treatment of non-small cell lung cancer. . Ann pharmacother . 1996; ;30: 5 : 501– 506 .
    [Google Scholar]
  11. 11. Johnson   SA., , Horper   P., , Hartobagyi   GN. , et al. , Vinorelbine: An overview. . Cancer Treat Rev . 1996; ;22: 2 : 127– 142 .
    [Google Scholar]
  12. 12. Thomas   PM., , Steve   D., , Robert   C. , et al. , Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high-Grade NHL. . N Eng J Med . 1998; ;339: : 21– 26 .
    [Google Scholar]
  13. 13. Vase   JM., , Link   BK., , Grossbard   ML. , et al. , Phase II Study of Rtuximab in combination with CHOP chemotherapy in patients with previously untreated aggressive NHL. . J Clin Oncol . 2001; ;19: : 389– 397 .
    [Google Scholar]
  14. 14. Coijfier B, Lepage E, Herbrecht R, et al. Rituximab plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma(DLCL):Interim results of a randomized Gela trial. 2000, Abstract, 950 ASH .
  15. 15. Cheson   BD., , Horning   SJ., , Coiffier   B. , et al. , Report of an International Workshop standarize response criteria for NHL. . J Clin Oncol . 1999; ;17: : 1244– 1253 .
    [Google Scholar]
  16. 16. Pelloski   CE., , Wilder   RB., , Ha   CS., , Hess   MA., , Cabanillas   f f., , Cox   JD. . Clinical stage IEA- IIEA orbital lymphomas:out come in the era of modern staging and treatment. . Radiother Oncol . 2001; ;59: 2 : 145– 151 .
    [Google Scholar]
  17. 17. Dupto   J., , Pavlov sky   S., , Woolley   P. , et al. , A comparison of two chemotherapy regimens, C-MOPP and BACOP, for the treatment of diffuse mixed (DML) and histiocytic (DHL) lymphomas. . Am Soc Clin Oncol (proceeding) Abstract . 1983; ; : 2215 .
    [Google Scholar]
  18. 18. Hagberg   H., , Bjorkholm   M., , Glimelius   B. , et al. , CHOP vs MEV for the treatment of the NHL of unfavorable histopathology: a randomized clinical trial. . Eur J Cancer Clin Oncol . 1985; ;21: : 175– 179 .
    [Google Scholar]
  19. 19. Gordon   LI., , Harrington   D., , Andersen   J. , et al. , Comparison of a second generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) or advanced diffuse NHL. . N Eng J Med . 1992; ;327: : 1342– 1349 .
    [Google Scholar]
  20. 20. Cooper   IA., , Ding   JC., , Mathews   JP. , et al. , A randomized comparison of MACOP-B and CHOP in intermediate grade NHL. . Am Soc Clin Oncol (Proceeding) Abstract . 1991; ;10: : 271 .
    [Google Scholar]
  21. 21. Gracia-Conde   J., , Vino las   N., , Est ape   J. . ProMACE-CytaBOM vs CHOP in the treatment of unfavorable lymphomas: A randomized trial. . Blood . 1991; ;78: suppl , Abstract No. 127a .
    [Google Scholar]
  22. 22. Tura   S., , Zinzani   PL., , Mazza   P. , et al. , F-MACHOP versus MACOP-B in the treatment of high grade malignant HHL. . Blood . 1991; ;78: Suppl : 109a .
    [Google Scholar]
  23. 23. Longo   DL., , DeVita   VT Jr., , Duffey   PL. , et al. , Superiority of Pro-MACE-CytaBOM over ProMCE-MOPP in the treatment of advanced diffuse aggressive lymphoma: result of a progressive randomized trial. . J Clin Oncol . 1991; ;9: : 25– 28 , Erratum, J Clin Oncol 1991, 9, 710 .
    [Google Scholar]
  24. 24. Koopler   H., , Pfluger   KH., , Eschenbach   I. , et al. , Sequential versus alternating chemotherapy for high grade NHL: a randomized multicenter trial. . Hematol Oncol . 1991; ;9: : 217– 223 .
    [Google Scholar]
  25. 25. The International Non-Hodgkin \s lymphoma prognostic factors project . A predictive model for aggressive Non-Hodgkin's lymphoma. . N Eng J Med . 1993; ;329: : 987– 994 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2007.1.14
Loading
  • Article Type: Research Article
Keyword(s): and Navelbine , Chemotherapy and Non-Hodgkin's Lymphoma
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error